---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-084908"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:41:09.097573+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents regains Nasdaq minimum bid price compliance

## Summary
- Received Nasdaq letter on July 26, 2024 confirming compliance after closing bid price at $1.00+ for 10 consecutive days through July 25.
- Previously, on May 22, 2024, Nasdaq notified CytoSorbents of non-compliance due to bid price below $1.00 for 30 consecutive days.
- Compliance had to be achieved by November 16, 2024; the company regained compliance early from July 12 to July 25.
- CEO Dr. Phillip Chan stated the company is now in full compliance, strengthening its position ahead of expected DrugSorb-ATR regulatory submissions.
- CytoSorbents continues aggressive cost cutting and operational progress on clinical, regulatory, and manufacturing fronts.

## SEC filing metadata
- accession: 0001104659-24-084908
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924084908/0001104659-24-084908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924084908/tm2420569d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-084908
- JSON: https://secwatch.observer/filing/0001104659-24-084908.json
- Plain text: https://secwatch.observer/filing/0001104659-24-084908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.